# Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection

> **NCT04600141** · PHASE3 · COMPLETED · sponsor: **University of Sao Paulo** · enrollment: 308 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** Heparin - Therapeutic dosage
- **DRUG:** Heparin - Prophylactic dosage

## Key facts

- **NCT ID:** NCT04600141
- **Lead sponsor:** University of Sao Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-10
- **Primary completion:** 2021-10-20
- **Final completion:** 2021-12-31
- **Target enrollment:** 308 (ACTUAL)
- **Last updated:** 2022-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04600141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04600141, "Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04600141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*